ReviewDeutsches Arzteblatt international2024
Dengue Fever—Diagnosis, Risk Stratification, and Treatment.
Review in Deutsches Arzteblatt international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Incidence of acute pancreatitis among hospitalized patients with dengue: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2026Pooled it
- Platelet Transfusion in Dengue-Associated Thrombocytopenia: A Systematic Review and Meta-Analysis.Revista da Sociedade Brasileira de Medicina Tropical · 2026Pooled it
- [Clinical characteristics and outcomes of neonatal dengue fever in Foshan].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Epidemiological characteristics and importation patterns of imported dengue fever in southwest border regions of China.PLoS neglected tropical diseases · 2026Article
- Assessing the Knowledge, Attitudes, and Practices (KAP) of Sudanese citizens regarding dengue fever prevention and control during the 2025 outbreak in Sudan: a multi-center cross-sectional study.BMC public health · 2026Article
- Metabolic and cardiovascular comorbidities as predictors of severe dengue in Vietnamese adults: a retrospective study, 2022-2024.Osong public health and research perspectives · 2026Article
- Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review.Pharmaceutics · 2026Review
- Evaluating the impact of the 'Four Pest-Free Villages' program on mosquito-borne disease control in Zhejiang Province, China: a cross-sectional study on knowledge, attitudes, and practices.Infectious diseases of poverty · 2026Article
- Evaluating the effectiveness of different intervention measures for a dengue outbreak in Hangzhou based on a dynamic model.BMC public health · 2026Article
- Integrating the Wei-Qi-Ying-Blood Theory with Modern Pathophysiology: A Multitarget Translational Framework for Dengue Management.International journal of general medicine · 2026Review
- Multi-omics insights into mosquito insecticide resistance for integrated vector management.PeerJ · 2026Review
- Machine Learning-Based QSAR Screening of Colombian Medicinal Flora for Potential Antiviral Compounds Against Dengue Virus: An In Silico Drug Discovery Approach.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Epidemiological Trends and Predictive Modeling of Dengue Fever in the Association of Southeast Asian Nations (ASEAN) Countries.Tropical medicine and infectious disease · 2025Article
- Exploiting host kinases to combat dengue virus infection and disease.Antiviral research · 2025Review
- A national report on 2024 dengue fever outbreak in Iran: has the game changed?BMC infectious diseases · 2025Article
- Human T Cell Responses to Flavivirus Vaccines.European journal of immunology · 2025Review
- Additional Points.Deutsches Arzteblatt international · 2025Article
- Dengue Fever in Children.Deutsches Arzteblatt international · 2025Article
- Increasing Relevance.Deutsches Arzteblatt international · 2025Article
- In Reply.Deutsches Arzteblatt international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue fever is a common infectious disease in the tropical and subtropical zones, with more than 100 million symptomatic cases per year. Mosquitoes of the genus Aedes (Aedes aegypti, Aedes albopticus) are vectors of the disease, and their spread has led to rising case numbers around the world. Physicians in Europe, too, are increasingly being confronted by this challenge.
methodsThis review is based on the findings of a selective search in international publication databases, as well as on the WHO guideline of 2009 and the current recommendations of the Robert Koch Institute.
resultsDengue fever takes a mild course in more than 90% of cases. Severe dengue fever, up to and including shock and/or mucosal hemorrhages, is rare and carries a mortality of 1-5%. The disease characteristically takes a triphasic course (febrile phase, critical phase, recovery phase). It is diagnosed by the direct demonstration of the pathogen (e.g., with the reverse transcriptase polymerase chain reaction [RT-PCR] up to day 5 of the illness) or by serology. Patients are classified into one of three risk groups depending on their findings and comorbidities and are then treated either as outpatients or in the hospital. The treatment is symptomatic, as no treatment directed against the cause of the disease is available. The key measures are adequate volume replacement and, in patients with hemorrhage, the transfusion of blood products. Preventive steps include vaccination after a documented initial infection and the meticulous avoidance of mosquito bites.
conclusionClimate change and global mobility have led to a worldwide increase in dengue fever. The disease only rarely takes a severe course. In such cases, rapid symptomatic treatment as needed is the key to the avoidance of severe complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.